Figure 3.

CD91- and LOX-1-dependence of presentation of gp96-chaperoned peptides by MHC II. Presentation of gp96-chaperoned peptides by immature bone marrow-derived DCs can be inhibited by CD91 ligands α₂-macroglobulin or antigen-negative gp96, but not by serum albumin. Re-presentation assays were performed as in Figure 1, in the presence of titrated concentrations of antigen-negative liver gp96 (A), α2M (B) or albumin (A, B) at the concentrations indicated. (C) Re-presentation assays were carried out in the presence of titrated concentrations of LDL, oxidized LDL or BSA, as indicated. Re-presentation was quantitated as in A and B. (D) Antibodies to scavenger receptors CD36, CD68, SR-A, MARCO or LOX-1 (10 µg/ml each) were included in the re-presentation assays as in C. In addition, antibodies to I-E^d (as a positive control) or K^d (as negative control) were included. Percent inhibition (as compared to activity in the absence of inhibiting antibody) is plotted.